Amgen stock dips as Lumakras combo trial ends; MariTide data now the next watch
Amgen Inc. shares were down 0.4% at $328.32 at 2:56 p.m. ET on Tuesday, after trading between $325.90 and $330.18.
Amgen stock slips to $330 as year-end pullback hits Wall Street; Fed minutes and MariTide updates in focus
Amgen shares fell 1% on Monday, ending the session down $3.30 at $329.63. StockAnalysis
Amgen Stock After Hours (AMGN) on Dec. 22, 2025: FDA Clears New Prolia/Xgeva Biosimilars, Fitch Upgrades Credit — What to Know Before the Dec. 23 Open
Amgen Inc. ended Monday, December 22, 2025, modestly higher, but the more important story for Tuesday’s open is what hit after the closing bell: fresh FDA approvals for new denosumab biosimilars that reference Amgen’s blockbuster bone-drug franchises Prolia and XGEVA—plus a credit-rating upgrade from Fitch that underscores improving balance-sheet flexibility.
Amgen Stock (AMGN) News Today: Trump Drug‑Price Deals, Analyst Forecasts, and What to Watch Next — Dec. 22, 2025
Amgen Inc. is back in the spotlight on Monday, December 22, 2025, as investors weigh a wave of White House drug‑pricing agreements, a fast‑moving “most‑favored‑nation” pricing push, and what it could all mean for Amgen’s earnings power in 2026. The stock traded higher in Monday’s session, with market data showing shares around $331.
Amgen (AMGN) Stock Week Ahead Forecast: Drug-Price Deal Fallout, Analyst Targets, and Year-End Catalysts to Watch (Dec. 22–26, 2025)
Amgen Inc. heads into the Christmas-shortened trading week with a fresh wave of policy headlines, a newly expanded FDA label win in rare disease, and a market still laser-focused on what comes next for its obesity pipeline. Shares last traded around $327.38, following a session that ranged roughly between $323 and $331—levels that now matter even more in holiday-thinned liquidity.
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch
Christmas week is usually about thin liquidity and shorter trading hours, not blockbuster headlines. But pharma and biotech stocks head into the final full week of the year with a rare mix of policy shockwaves, deal-making, and FDA-driven volatility—all clustered around Dec. 19–21, 2025.
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)
As of December 20, 2025, healthcare stocks are heading into year-end with a rare mix of policy clarity and policy risk—often at the same time. In the past 48 hours, the sector has been hit by major U.S. drug-pricing announcements, renewed focus on insurance premiums, and a fresh run of deal and IPO headlines that are reshaping investor expectations for 2026. Reuters+3Reuters+3Reuters+3
Amgen Stock (AMGN) News Today: TrumpRx Drug-Price Deal, FDA Approvals, Dividend Update, and 2026 Analyst Forecasts
December 20, 2025 — Amgen Inc. is closing out the year with a rare combination of near-term policy headlines and company-specific catalysts that matter to investors: a new U.S. drug-pricing deal tied to the TrumpRx rollout, fresh FDA approvals that expand the growth runway, reaffirmed shareholder returns via dividends, and a split—but active—Wall Street outlook heading into 2026.
Amgen Stock (AMGN) News Today, Dec. 16, 2025: Dividend Boost, FDA Wins, Analyst Targets, and Key 2026 Catalysts
Amgen Inc. is in focus on December 16, 2025, as investors weigh a fresh dividend raise, recent regulatory momentum, and a pipeline narrative that stretches from cardiovascular outcomes to the high-stakes obesity race.
Amgen (AMGN) Stock: What to Know Before the U.S. Market Opens on Dec. 15, 2025
Amgen Inc. heads into Monday’s session after a news-heavy stretch that has reinforced two familiar pillars of the large-cap biotech story: a steady capital-return profile and a pipeline/label-expansion engine that can still surprise to the upside.
Amgen (AMGN) Stock Near Record Highs on Obesity Drug Hopes – Is It Still a Buy in December 2025?
Amgen Inc. has quietly turned into one of 2025’s standout large‑cap healthcare winners. The biotech heavyweight is trading just below fresh 52‑week highs, powered by a clean sweep of earnings beats, a deepening obesity‑drug story around its MariTide program, and full FDA approval for its lung‑cancer therapy Imdelltra. At the same time, investors are grappling with tax and patent overhangs, looming drug price pressure and an increasingly crowded obesity market.
Amgen (AMGN) Stock Hits New 52‑Week High as Obesity Drug Bets and Analyst Upgrades Fuel 2025 Rally
Amgen Inc. is closing out 2025 on a powerful upswing. As of the close on December 3, 2025, Amgen shares finished at $345.42, up about 2% on the day, and nudged higher in after-hours trading.StockAnalysis The move pushed the biotech giant to a fresh 52‑week high near $345.95, extending a year-to-date rally of roughly 35%–37% and a one‑year gain of more than 25%.Investing.com+1
Amgen Stock (AMGN) Today: Q3 2025 Earnings Beat, MariTide Obesity Drug Outlook and 2030 Price Forecast
Amgen Inc. closed today at $337.49, down about 2.3% on the session, according to real‑time quote data. StockAnalysis
Amgen (AMGN) Stock Near Record Highs Before December 1, 2025 Open: Price, News, Analyst Targets and Forecast
THOUSAND OAKS, Calif. – November 30, 2025 – Amgen Inc. heads into the new trading week sitting at an all‑time closing high, with a flurry of analyst upgrades, institutional activity and bullish technical signals setting the stage before the U.S. market opens on Monday, December 1, 2025.
AI Rally Hits Speed Bump as Futures Fall – Key Facts Before the Nov. 4 Market Open
Stock index futures are firmly in the red before the opening bell, indicating Wall Street will give back some of Monday’s gains. S&P 500 futures are down roughly 0.9% and Nasdaq 100 futures off 1.2%, with Dow futures –0.7%seekingalpha.comseekingalpha.com. This comes after the Nasdaq Composite and S&P 500 ticked higher yesterday, buoyed by excitement over a big Amazon–OpenAI AI partnership, even as the Dow slippedeconomictimes.indiatimes.com. That optimism has proved short-lived; by early Tuesday, futures reversed as investors refocus on stretched valuations in the tech sector and worry that the AI boom may have overshot fundamentalsswissinfo.chswissinfo.ch.